Zou_2023_J.Enzyme.Inhib.Med.Chem_38_2270781

Reference

Title : Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer's disease - Zou_2023_J.Enzyme.Inhib.Med.Chem_38_2270781
Author(s) : Zou D , Liu R , Lv Y , Guo J , Zhang C , Xie Y
Ref : J Enzyme Inhib Med Chem , 38 :2270781 , 2023
Abstract :

Alzheimer's disease (AD) is a progressive brain disease characterised by progressive memory loss and cognition impairment, ultimately leading to death. There are three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine, AChEIs) for the symptomatic treatment of AD. Monoamine oxidase B (MAO-B) has been considered to contribute to pathologies of AD. Therefore, we reviewed the dual inhibitors of acetylcholinesterase (AChE) and MAO-B developed in the last five years. In this review, these dual-target inhibitors were classified into six groups according to the basic parent structure, including chalcone, coumarin, chromone, benzo-fused five-membered ring, imine and hydrazine, and other scaffolds. Their design strategies, structure-activity relationships (SARs), and molecular docking studies with AChE and MAO-B were analysed and discussed, giving valuable insights for the subsequent development of AChE and MAO-B dual inhibitors. Challenges in the development of balanced and potent AChE and MAO-B dual inhibitors were noted, and corresponding solutions were provided.

PubMedSearch : Zou_2023_J.Enzyme.Inhib.Med.Chem_38_2270781
PubMedID: 37955252

Related information

Citations formats

Zou D, Liu R, Lv Y, Guo J, Zhang C, Xie Y (2023)
Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer's disease
J Enzyme Inhib Med Chem 38 :2270781

Zou D, Liu R, Lv Y, Guo J, Zhang C, Xie Y (2023)
J Enzyme Inhib Med Chem 38 :2270781